1307803-06-0

Upstream product

• 1307803-03-7 (1-(2-chloro-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-yl)methanol 
• 1307803-02-6 ethyl 1-(2-chloro-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carboxylate 
• 1307801-59-7 (1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methanol 
• 85290-78-4 ethyl 3-methylpyrazole-4-carboxylate 

Downstream Products

• 1307801-93-9 2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methylamino)ethanol 
• 1307802-53-4 2,2-dimethyl-1-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-1H-pyrrol-3-yl)methyl)-1,4-diazepan-1-yl)propan-1-one 

Relevant academic research and scientific papers

KINASE INHIBITORS

The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.